You are here:

umeclidinium (Incruse)

Advice

following a full submission:

umeclidinium (Incruse®) is accepted for use within NHS Scotland.

Indication under review: as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Two randomised controlled, phase III studies demonstrated that after 12 and 24 weeks of treatment umeclidinium improved lung function compared with placebo in patients with moderate to severe COPD.  There was also improvement in symptomatic outcomes such as dyspnoea. 

Umeclidinium is an alternative to other long-acting muscarinic antagonists (LAMAs).

Drug Details

Drug Name: umeclidinium (Incruse)
SMC Drug ID: 1004/14
Manufacturer: GlaxoSmithKline UK Ltd
Indication: as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
BNF Category:
Submission Type: Full submission
Status: Accepted
Date Advice Published: 8 December 2014

Back